HIGHTIDE-B (02511.HK): Appoints Dr. Filip Surmont as CMO to Strengthen Cardio‑Kidney‑Metabolic Disease Portfolio

NewTimeSpace News: On February 2, the Board of Directors of HighTide Therapeutics, Inc. (02511.HK) announced the appointment of Dr. Filip Surmont as the Company’s Chief Medical Officer. He will take full charge of the Company’s medical strategy, clinical development and related medical affairs, with the goal of advancing the R&D progress and enhancing the value of the Company in the field of cardio‑kidney‑metabolic diseases.

Dr. Surmont boasts over 30 years of extensive experience in the medical and pharmaceutical sectors, including 18 years in leadership roles at multinational pharmaceutical companies and 16 years of clinical practice experience. He previously held senior medical leadership positions at Wyeth, Pfizer, and AstraZeneca, and has led medical affairs across multiple regions globally. His distinguished career achievements include contributing to the success of dapagliflozin as a blockbuster drug; spearheading the “ACT on HF” project in China, which benefited 200,000 heart failure patients; and pioneering the Anti‑Inflammatory Reliever (AIR) therapy strategy for asthma, which has impacted approximately 50 million patients worldwide.

As a globally renowned medical expert, Dr. Surmont has long been dedicated to research on metabolic and cardiovascular‑related diseases. His numerous research findings have been published in top‑tier journals such asThe Lancet Diabetes & Endocrinologyand theJournal of the American College of Cardiology. He holds a Doctor of Medicine degree and a Master’s degree in Sports Medicine from Ghent University in Belgium.